The Supreme Court may vote to overturn abortion rights; Washington state reaches a $518 million settlement with 3 opioid distributors; a new study finds 7 hours of sleep is the optimal total for people of middle and old ages.
POLITICO is reporting that the Supreme Court will likely vote to overturn the landmark Roe v Wade decision, as well as the Planned Parenthood v Casey ruling, that have guaranteed federal constitutional protections of abortion rights for Americans. The initial draft majority opinion, written by Justice Samuel Alito, contended that Roe v Wade was ill conceived and deeply flawed. The court’s holding will not be final until the draft majority opinion is published, which is expected to be in the next 2 months. The immediate impact of the ruling would allow each state to decide whether to restrict or ban abortions.
McKesson announced today, May 3, that it and fellow opioid distributors AmerisourceBergen and Cardinal Health reached a $518 million settlement with Washington state over their role in fueling the state’s opioid epidemic. Reuters is reporting that the fee is greater than Washington would have received if it opted to accept the nationwide opioid settlement involving the 3 drug distributors and Johnson & Johnson, which was finalized in February. Although denying wrongdoing, the opioid distributors said the settlement would provide meaningful relief to communities ravaged by the opioid epidemic in the United States.
Findings of a study published recently in Nature Aging indicate that 7 hours is the optimal amount of sleep for people of middle and old ages. As reported by CNN, research on almost 500,000 adults aged 38 to 73 years enrolled in the UK Biobank, including 94% who are White, showed that participants who reported insufficient or excessive sleep were associated with cognitive issues, such as impaired attention, memory, and decision-making. People who slept 7 hours were conversely linked with better cognition and mental health.
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More